Toronto, Canada-based life sciences startup Cora Therapeutics raised USD 1 million in seed funding. The seed round took place on March 27, 2023. NYC, USA-based Irongate Capital Advisors led the financing for the company. The recent funding represents the closure of the second round of seed financing.
So far, the company’s total funding stands at USD 1.8 million.
Purpose of financing for Cora Therapeutics
With the latest proceeds from the seed funding, the company seeks to accelerate the launch of DNA HALO in North America. Cora Therapeutics has plans to target medical professionals, medical imaging patients, air travel professionals, frequent fliers, military personnel, as well as the health-conscious public.
What the Cora Therapeutics official has to say
Speaking on the recent fundraise, Dr Kieran Murphy said, “We have demonstrated the efficacy of DNA HALO in protecting DNA from radiation-induced injuries. It is now time for us to commercialize! We are thrilled to have closed this round, and we are grateful for the support of all our investors. Irongate’s investment validates our mission and is essential for our next stage of growth. We are truly excited to bring this revolutionary product to the market.”
What the lead investor has to add
Hamlet Yousef, Managing Partner from Irongate, further added, “Our mission is to direct capital to the highest-performing investments in the advanced technology arena, with a specific focus on dual-use innovations. We are excited about the broad applications for DNA HALO in the medical, consumer and military communities. We believe DNA Halo can help address the issues noted in a recent Pentagon study highlighting the increased risk of cancer among aviators and astronauts. Our team is excited to partner with Dr Murphy and the team at Cora Therapeutics to help military professionals, the medical community, and beyond.”
About the company
Dr Keiran Murphy launched Cora Therapeutics. The company is on a mission to deliver innovative research-based solutions for whole-body health. Cora Therapeutics’ offering DNA HALO is a potent formulation of antioxidants protecting both cellular and mitochondrial DNA from nuclear as well as medical radiation. DNA HALO is a patented blend of ingredients from natural sources, compliant with strict U.S. as well as Canadian regulatory bodies. DNA HALO helps to prevent cell damage from free radicals due to oxidative stress.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
